Abstract
Evaluate radiologic outcomes of radiofrequency ablation and vertebral augmentation (RFA-VA) for the treatment of painful osseous spine metastatic disease. A retrospective review of patients who underwent ablations of vertebral body (VB) from January 2012 through August 2019 was performed. 166 patients, with 264 VB lesions from a single tertiary academic medical center were included in the study. 46.4% were men with the average age of 60.2. Data was collected from the medical record. Based on imaging characteristics on postprocedural MR, CT, or PET, outcomes of the treated osseous disease were recorded as disease progression, residual disease, or treatment changes. The average length of time between RFA-VA and imaging was 283 days (range, 4-2152 days). 227 lesions (86.0%) had postprocedural imaging with 57.0% undergoing an MR examination. Of these 227 lesions, 145 (54.9%) had treatment related changes without evidence of residual disease. Thirty-five (13.3%) demonstrated enhancement within the procedural bed, consistent with residual disease. Forty-seven (17.8%) had imaging characteristics consistent with disease progression. RFA-VA is a minimally invasive and effective percutaneous treatment option which demonstrates durable locoregional control for patients with painful osseous spine metastatic disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
